Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Monoacylglycerol Lipase Inhibition in Human and Rodent Systems Supports Clinical Evaluation of Endocannabinoid Modulators.

Clapper JR, Henry CL, Niphakis MJ, Knize AM, Coppola AR, Simon GM, Ngo N, Herbst RA, Herbst DM, Reed AW, Cisar JS, Weber OD, Viader A, Alexander JP, Cunningham ML, Jones TK, Fraser IP, Grice CA, Ezekowitz RAB, O'Neill GP, Blankman JL.

J Pharmacol Exp Ther. 2018 Dec;367(3):494-508. doi: 10.1124/jpet.118.252296. Epub 2018 Oct 10.

PMID:
30305428
2.

Identification of ABX-1431, a Selective Inhibitor of Monoacylglycerol Lipase and Clinical Candidate for Treatment of Neurological Disorders.

Cisar JS, Weber OD, Clapper JR, Blankman JL, Henry CL, Simon GM, Alexander JP, Jones TK, Ezekowitz RAB, O'Neill GP, Grice CA.

J Med Chem. 2018 Oct 25;61(20):9062-9084. doi: 10.1021/acs.jmedchem.8b00951. Epub 2018 Aug 23.

PMID:
30067909
3.

In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects.

Ignatowska-Jankowska BM, Ghosh S, Crowe MS, Kinsey SG, Niphakis MJ, Abdullah RA, Tao Q, O' Neal ST, Walentiny DM, Wiley JL, Cravatt BF, Lichtman AH.

Br J Pharmacol. 2014 Mar;171(6):1392-407. doi: 10.1111/bph.12298.

5.

Selective monoacylglycerol lipase inhibitors: antinociceptive versus cannabimimetic effects in mice.

Ignatowska-Jankowska B, Wilkerson JL, Mustafa M, Abdullah R, Niphakis M, Wiley JL, Cravatt BF, Lichtman AH.

J Pharmacol Exp Ther. 2015 May;353(2):424-32. doi: 10.1124/jpet.114.222315. Epub 2015 Mar 11.

6.
7.

Fever Is Mediated by Conversion of Endocannabinoid 2-Arachidonoylglycerol to Prostaglandin E2.

Kita Y, Yoshida K, Tokuoka SM, Hamano F, Yamazaki M, Sakimura K, Kano M, Shimizu T.

PLoS One. 2015 Jul 21;10(7):e0133663. doi: 10.1371/journal.pone.0133663. eCollection 2015.

8.

The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice.

Wilkerson JL, Ghosh S, Mustafa M, Abdullah RA, Niphakis MJ, Cabrera R, Maldonado RL, Cravatt BF, Lichtman AH.

Neuropharmacology. 2017 Mar 1;114:156-167. doi: 10.1016/j.neuropharm.2016.11.015. Epub 2016 Nov 25.

9.

Comparative biochemical characterization of the monoacylglycerol lipase inhibitor KML29 in brain, spinal cord, liver, spleen, fat and muscle tissue.

Pasquarelli N, Porazik C, Hanselmann J, Weydt P, Ferger B, Witting A.

Neuropharmacology. 2015 Apr;91:148-56. doi: 10.1016/j.neuropharm.2014.12.001. Epub 2014 Dec 12.

PMID:
25497453
10.

Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysis.

Carey CE, Agrawal A, Zhang B, Conley ED, Degenhardt L, Heath AC, Li D, Lynskey MT, Martin NG, Montgomery GW, Wang T, Bierut LJ, Hariri AR, Nelson EC, Bogdan R.

J Abnorm Psychol. 2015 Nov;124(4):860-77. doi: 10.1037/abn0000079.

11.

Low mRNA expression and activity of monoacylglycerol lipase in human SH-SY5Y neuroblastoma cells.

Szeremeta J, Karlsson J, Alhouayek M, Fowler CJ.

Prostaglandins Other Lipid Mediat. 2019 Apr 9. pii: S1098-8823(19)30019-X. doi: 10.1016/j.prostaglandins.2019.04.003. [Epub ahead of print]

PMID:
30978461
12.

Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain.

Guindon J, Guijarro A, Piomelli D, Hohmann AG.

Br J Pharmacol. 2011 Aug;163(7):1464-78. doi: 10.1111/j.1476-5381.2010.01192.x.

13.

Full Fatty Acid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimimetic Side Effects in Mice.

Ghosh S, Kinsey SG, Liu QS, Hruba L, McMahon LR, Grim TW, Merritt CR, Wise LE, Abdullah RA, Selley DE, Sim-Selley LJ, Cravatt BF, Lichtman AH.

J Pharmacol Exp Ther. 2015 Aug;354(2):111-20. doi: 10.1124/jpet.115.222851. Epub 2015 May 21.

14.

Inhibition of monoacylglycerol lipase terminates diazepam-resistant status epilepticus in mice and its effects are potentiated by a ketogenic diet.

Terrone G, Pauletti A, Salamone A, Rizzi M, Villa BR, Porcu L, Sheehan MJ, Guilmette E, Butler CR, Piro JR, Samad TA, Vezzani A.

Epilepsia. 2018 Jan;59(1):79-91. doi: 10.1111/epi.13950. Epub 2017 Nov 24.

15.

The antinociceptive triterpene β-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting cannabinoid receptors.

Chicca A, Marazzi J, Gertsch J.

Br J Pharmacol. 2012 Dec;167(8):1596-608. doi: 10.1111/j.1476-5381.2012.02059.x.

16.

Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo.

Bisogno T, Ortar G, Petrosino S, Morera E, Palazzo E, Nalli M, Maione S, Di Marzo V; Endocannabinoid Research Group.

Biochim Biophys Acta. 2009 Jan;1791(1):53-60. doi: 10.1016/j.bbalip.2008.10.007. Epub 2008 Nov 5.

PMID:
19027877
17.

Multiple Forms of Endocannabinoid and Endovanilloid Signaling Regulate the Tonic Control of GABA Release.

Lee SH, Ledri M, Tóth B, Marchionni I, Henstridge CM, Dudok B, Kenesei K, Barna L, Szabó SI, Renkecz T, Oberoi M, Watanabe M, Limoli CL, Horvai G, Soltesz I, Katona I.

J Neurosci. 2015 Jul 8;35(27):10039-57. doi: 10.1523/JNEUROSCI.4112-14.2015.

18.

Inhibition of monoacylglycerol lipase attenuates nonsteroidal anti-inflammatory drug-induced gastric hemorrhages in mice.

Kinsey SG, Nomura DK, O'Neal ST, Long JZ, Mahadevan A, Cravatt BF, Grider JR, Lichtman AH.

J Pharmacol Exp Ther. 2011 Sep;338(3):795-802. doi: 10.1124/jpet.110.175778. Epub 2011 Jun 9.

19.

Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB1 receptor-mediated discriminative stimulus in mice.

Owens RA, Mustafa MA, Ignatowska-Jankowska BM, Damaj MI, Beardsley PM, Wiley JL, Niphakis MJ, Cravatt BF, Lichtman AH.

Neuropharmacology. 2017 Oct;125:80-86. doi: 10.1016/j.neuropharm.2017.06.032. Epub 2017 Jun 30.

20.

Δ9-tetrahydrocannabinol and endocannabinoid degradative enzyme inhibitors attenuate intracranial self-stimulation in mice.

Wiebelhaus JM, Grim TW, Owens RA, Lazenka MF, Sim-Selley LJ, Abdullah RA, Niphakis MJ, Vann RE, Cravatt BF, Wiley JL, Negus SS, Lichtman AH.

J Pharmacol Exp Ther. 2015 Feb;352(2):195-207. doi: 10.1124/jpet.114.218677. Epub 2014 Nov 14.

Supplemental Content

Support Center